8-K/A filed September 16, 2026, 4:06 PM ET ticker CDNA CIK 0001217234

M&A confidence high sentiment negative materiality 0.55

CareDx files Naveris 2025 financials: revenue $34.3M, net loss $3.9M, going concern doubt

CareDx, Inc.

Naveris FY2025 revenue $34.337M; net loss $3.882M; accumulated deficit $65.049M.
Substantial doubt about going concern; recurring operating losses and negative operating cash flow.
Cash and equivalents $15.401M plus restricted cash $0.890M at Dec 31, 2025.
Naveris is commercial-stage precision oncology; NavDx TTMV-HPV DNA test for viral-induced cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.